Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

NCT05635487 is registered in ClinicalTrials.gov with Shengjing Hospital as lead sponsor.

NCT NCT05635487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05635487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Lead sponsor
Shengjing Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
March 16, 2023
Completion date
February 28, 2030
Enrollment
65 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer